Literature DB >> 27270171

Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions.

Martina Absinta, Pascal Sati, Matthew Schindler, Emily C Leibovitch, Joan Ohayon, Tianxia Wu, Alessandro Meani, Massimo Filippi, Steven Jacobson, Irene C M Cortese, Daniel S Reich.   

Abstract

BACKGROUND: In some active multiple sclerosis (MS) lesions, a strong immune reaction at the lesion edge may contain growth and thereby isolate the lesion from the surrounding parenchyma. Our previous studies suggest that this process involves opening of the blood-brain barrier in capillaries at the lesion edge, seen on MRI as centripetal contrast enhancement and a colocalized phase rim. We hypothesized that using these features to characterize early lesion evolution will allow in vivo tracking of tissue degeneration and/or repair, thus improving the evaluation of potential therapies for chronic active lesions.
METHODS: Centripetally and centrifugally enhancing lesions were studied in 17 patients with MS using 7-tesla MRI. High-resolution, susceptibility-weighted, T1-weighted (before/after gadolinium), and dynamic contrast-enhanced scans were acquired at baseline and months 1, 3, 6, and 12. For each lesion, time evolution of the phase rim, lesion volume, and T1 hypointensity were assessed. In autopsies of 3 progressive MS cases, the histopathology of the phase rim was determined.
RESULTS: In centripetal lesions, a phase rim colocalized with initial contrast enhancement. In 12 of 22, this phase rim persisted after enhancement resolved. Compared with centripetal lesions with transient rim, those with persistent rim had less volume shrinkage and became more T1 hypointense between months 3 and 12. No centrifugal lesions developed phase rims at any time point. Pathologically, persistent rims corresponded to an iron-laden inflammatory myeloid cell population at the edge of chronic demyelinated lesions.
CONCLUSION: In early lesion evolution, a persistent phase rim in lesions that shrink least and become more T1 hypointense over time suggests that the rim might mark failure of early lesion repair and/or irreversible tissue damage. In later stages of MS, phase rim lesions continue to smolder, exerting detrimental effects on affected brain tissue. TRIAL REGISTRATION: NCT00001248. FUNDING: The Intramural Research Program of NINDS supported this study.

Entities:  

Mesh:

Year:  2016        PMID: 27270171      PMCID: PMC4922708          DOI: 10.1172/JCI86198

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  53 in total

1.  A serial in vivo 7T magnetic resonance phase imaging study of white matter lesions in multiple sclerosis.

Authors:  Wei Bian; Kristin Harter; Kathryn E Hammond-Rosenbluth; Janine M Lupo; Duan Xu; Douglas Ac Kelley; Daniel B Vigneron; Sarah J Nelson; Daniel Pelletier
Journal:  Mult Scler       Date:  2012-05-28       Impact factor: 6.312

2.  Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging.

Authors:  David Pitt; Aaron Boster; Wei Pei; Eric Wohleb; Adam Jasne; Cherian R Zachariah; Kottil Rammohan; Michael V Knopp; Petra Schmalbrock
Journal:  Arch Neurol       Date:  2010-07

3.  CNS sterile injury: just another wound healing?

Authors:  Ravid Shechter; Michal Schwartz
Journal:  Trends Mol Med       Date:  2012-12-30       Impact factor: 11.951

4.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

Review 5.  Immunosenescence of microglia and macrophages: impact on the ageing central nervous system.

Authors:  Khalil S Rawji; Manoj K Mishra; Nathan J Michaels; Serge Rivest; Peter K Stys; V Wee Yong
Journal:  Brain       Date:  2016-01-29       Impact factor: 13.501

6.  Biophysical mechanisms of MRI signal frequency contrast in multiple sclerosis.

Authors:  Dmitriy A Yablonskiy; Jie Luo; Alexander L Sukstanskii; Aditi Iyer; Anne H Cross
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-13       Impact factor: 11.205

7.  Demyelination versus remyelination in progressive multiple sclerosis.

Authors:  Stephan Bramow; Josa M Frischer; Hans Lassmann; Nils Koch-Henriksen; Claudia F Lucchinetti; Per S Sørensen; Henning Laursen
Journal:  Brain       Date:  2010-09-20       Impact factor: 13.501

8.  Postmortem magnetic resonance imaging to guide the pathologic cut: individualized, 3-dimensionally printed cutting boxes for fixed brains.

Authors:  Martina Absinta; Govind Nair; Massimo Filippi; Abhik Ray-Chaudhury; Maria I Reyes-Mantilla; Carlos A Pardo; Daniel S Reich
Journal:  J Neuropathol Exp Neurol       Date:  2014-08       Impact factor: 3.685

9.  Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions.

Authors:  Veela Mehta; Wei Pei; Grant Yang; Suyang Li; Eashwar Swamy; Aaron Boster; Petra Schmalbrock; David Pitt
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

Review 10.  Neuroinflammation and M2 microglia: the good, the bad, and the inflamed.

Authors:  Jonathan D Cherry; John A Olschowka; M Kerry O'Banion
Journal:  J Neuroinflammation       Date:  2014-06-03       Impact factor: 8.322

View more
  72 in total

Review 1.  The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Authors:  Kedar R Mahajan; Daniel Ontaneda
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

2.  Ultra-high-field (7.0 Tesla and above) MRI is now necessary to make the next step forward in understanding MS pathophysiology - YES.

Authors:  Francesca Bagnato; John C Gore
Journal:  Mult Scler       Date:  2016-12-16       Impact factor: 6.312

3.  Dark Rims: Novel Sequence Enhances Diagnostic Specificity in Multiple Sclerosis.

Authors:  J-M Tillema; S D Weigand; M Dayan; Y Shu; O H Kantarci; C F Lucchinetti; J D Port
Journal:  AJNR Am J Neuroradiol       Date:  2018-04-26       Impact factor: 3.825

4.  Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions.

Authors:  Ulrike W Kaunzner; Yeona Kang; Shun Zhang; Eric Morris; Yihao Yao; Sneha Pandya; Sandra M Hurtado Rua; Calvin Park; Kelly M Gillen; Thanh D Nguyen; Yi Wang; David Pitt; Susan A Gauthier
Journal:  Brain       Date:  2019-01-01       Impact factor: 13.501

Review 5.  Clinical 7-T MRI for neuroradiology: strengths, weaknesses, and ongoing challenges.

Authors:  Brian J Burkett; Andrew J Fagan; Joel P Felmlee; David F Black; John I Lane; John D Port; Charlotte H Rydberg; Kirk M Welker
Journal:  Neuroradiology       Date:  2021-01-02       Impact factor: 2.804

Review 6.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

Review 7.  Clinical applications of ultra-high field magnetic resonance imaging in multiple sclerosis.

Authors:  Matilde Inglese; Lazar Fleysher; Niels Oesingmann; Maria Petracca
Journal:  Expert Rev Neurother       Date:  2018-01-30       Impact factor: 4.618

8.  The "central vein sign" in inflammatory demyelination: The role of fibrillar collagen type I.

Authors:  Martina Absinta; Govind Nair; Maria Chiara G Monaco; Dragan Maric; Nathanael J Lee; Seung-Kwon Ha; Nicholas J Luciano; Pascal Sati; Steven Jacobson; Daniel S Reich
Journal:  Ann Neurol       Date:  2019-03-30       Impact factor: 10.422

Review 9.  Multiple Sclerosis.

Authors:  Daniel S Reich; Claudia F Lucchinetti; Peter A Calabresi
Journal:  N Engl J Med       Date:  2018-01-11       Impact factor: 91.245

10.  Identification of Chronic Active Multiple Sclerosis Lesions on 3T MRI.

Authors:  M Absinta; P Sati; A Fechner; M K Schindler; G Nair; D S Reich
Journal:  AJNR Am J Neuroradiol       Date:  2018-05-03       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.